ストックスクリーナーアプリを入手
5.31
5.35%
-0.30
アフターアワーズ：
5.41
0.10
+1.88%
前日終値:
$5.61
開ける：
$5.6
24時間の取引高:
867.54K
Relative Volume:
0.84
時価総額：
$413.70M
収益：
$14.79M
当期純損益:
$-102.44M
株価収益率:
-1.7467
EPS:
-3.04
ネットキャッシュフロー:
$-91.73M
1週間 パフォーマンス:
-5.85%
1か月 パフォーマンス:
-7.01%
6か月 パフォーマンス:
+1.34%
1年 パフォーマンス:
+31.76%
1日の値動き範囲:
$5.232
$5.60
1週間の範囲:
$5.165
$5.77
52週間の値動き範囲:
$2.41
$7.37
Solid Biosciences Inc Stock (SLDB) Company Profile
名前
Solid Biosciences Inc
セクター
電話
617-337-4680
住所
500 RUTHERFORD AVENUE, CHARLESTOWN, MA
SLDB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SLDB
Solid Biosciences Inc
|
5.31 | 437.08M | 14.79M | -102.44M | -91.73M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-04 | 開始されました | Needham | Buy |
| 2025-06-26 | 開始されました | Citigroup | Buy |
| 2025-01-08 | 開始されました | Truist | Buy |
| 2024-12-13 | 開始されました | Wedbush | Outperform |
| 2024-12-10 | 開始されました | JMP Securities | Mkt Outperform |
| 2024-07-15 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-06-24 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-05-31 | 再開されました | Piper Sandler | Overweight |
| 2024-03-28 | 開始されました | William Blair | Outperform |
| 2024-03-15 | 開始されました | Citigroup | Buy |
| 2024-03-14 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-12-08 | 開始されました | H.C. Wainwright | Buy |
| 2021-07-12 | 開始されました | Piper Sandler | Neutral |
| 2021-05-27 | 開始されました | Jefferies | Buy |
| 2021-03-16 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-03-09 | 開始されました | Barclays | Overweight |
| 2021-01-08 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-07-28 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-05-07 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-10-11 | 開始されました | Evercore ISI | Outperform |
| 2019-08-29 | ダウングレード | Citigroup | Neutral → Sell |
| 2019-08-19 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-08-16 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2019-05-14 | ダウングレード | Credit Suisse | Neutral → Underperform |
| 2019-05-14 | ダウングレード | Goldman | Neutral → Sell |
| 2019-02-08 | アップグレード | Citigroup | Sell → Neutral |
| 2019-02-08 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2018-11-06 | 開始されました | Citigroup | Sell |
| 2018-09-06 | 開始されました | Credit Suisse | Neutral |
すべてを表示
Solid Biosciences Inc (SLDB) 最新ニュース
Can Solid Biosciences Inc. stock rebound after recent weaknessWeekly Trading Summary & Real-Time Price Movement Reports - ulpravda.ru
Solid Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference - Yahoo Finance
Solid Biosciences (NASDAQ:SLDB) Shares Down 2.2%Here's What Happened - MarketBeat
Solid Biosciences reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Published on: 2026-01-01 04:47:43 - moha.gov.vn
Aug Reactions: Is Solid Biosciences Inc stock a buy before product launches2025 AllTime Highs & Risk Controlled Stock Pick Alerts - moha.gov.vn
Is Solid Biosciences Inc. stock a buy before product launchesJuly 2025 Setups & Smart Investment Allocation Tips - DonanımHaber
Cartography Biosciences’ CBI-1214 gains IND clearance - BioWorld MedTech
Update Report: Is Solid Biosciences Inc. stock a bargain at current levels2025 Performance Recap & Long-Term Investment Growth Plans - Улправда
Solid Biosciences stock rating reiterated at Market Outperform by Citizens - Investing.com Australia
Gene Therapy Milestones And Collaborations Keep Solid Biosciences In Focus - RTTNews
Solid Biosciences stock rises after Duchenne added to newborn screening list - Investing.com Australia
Solid Biosciences (SLDB) Sees Duchenne Screening Advancement in US - GuruFocus
Solid Biosciences Supports Duchenne Muscular Dystrophy Inclusion in U.S. Newborn Screening Recommendations - Quiver Quantitative
Solid Biosciences Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services - The Manila Times
U.S. newborns will now be screened for Duchenne muscular dystrophy - Stock Titan
Solid Biosciences (SLDB) Gains Attention with Duchenne Muscular Dystrophy Inclusion - GuruFocus
Sarepta's Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences' (SLDB) SGT-003 in Duchenne Therapy - Finviz
Sarepta’s Elevidys Safety Concerns Open Major Opportunity for Solid Biosciences’ (SLDB) SGT-003 in Duchenne Therapy - Insider Monkey
Solid Biosciences Inc. (NASDAQ:SLDB) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Solid Biosciences to Showcase Proprietary Next-Generation Capsid AAV-SLB101 and Cardiac Gene Therapy Pipeline at the 22nd Global CardioVascular Clinical Trialists (CVCT) Forum - GlobeNewswire
Bollard Group LLC Acquires New Holdings in Solid Biosciences Inc. $SLDB - MarketBeat
Needham & Company LLC Upgrades Solid Biosciences (NASDAQ:SLDB) to Moderate Buy - MarketBeat
Geode Capital Management LLC Purchases 979,294 Shares of Solid Biosciences Inc. $SLDB - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) CTO Sells 2,701 Shares of Stock - MarketBeat
Insider Selling: Solid Biosciences (NASDAQ:SLDB) COO Sells 4,932 Shares of Stock - MarketBeat
Solid Biosciences (NASDAQ:SLDB) CEO Sells 10,808 Shares - MarketBeat
Jessie Hanrahan Sells 4,483 Shares of Solid Biosciences (NASDAQ:SLDB) Stock - MarketBeat
Solid Biosciences CEO Cumbo sells $55k in shares By Investing.com - Investing.com Canada
Solid Biosciences CEO Cumbo sells $55k in shares - Investing.com India
Solid Biosciences Executives Sell Shares to Cover Taxes - TradingView — Track All Markets
Solid Biosciences: Better Positioned To Compete In DMD Gene Therapy, Says Bullish Analyst - Benzinga
This AutoZone Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Solid Biosciences (SLDB) Receives Buy Rating Amid Competitive Ad - GuruFocus
SLDB Receives "Buy" Rating from Needham with $16 Target Price | SLDB Stock News - GuruFocus
How Solid Biosciences Inc. stock performs in rising dollar environment2025 Breakouts & Breakdowns & Safe Capital Allocation Plans - Newser
Solid Biosciences’ SGT-212 gains FDA rare paediatric disease status - Yahoo
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Solid Biosciences (Nasdaq: SLDB) issues 23,284 RSUs under 2024 inducement plan - Stock Titan
Solid Biosciences' SGT-212 Receives Rare Pediatric Disease Designation to Treat Friedreich's Ataxia - marketscreener.com
Solid Biosciences receives FDA rare pediatric disease designation for SGT-212 dual route of administration gene therapy - marketscreener.com
Solid Biosciences (SLDB) Gains Key FDA Designation for Gene Ther - GuruFocus
Solid Biosciences Receives FDA Rare Pediatric Disease and Fast Track Designations for SGT-212, a Novel Gene Therapy for Friedreich’s Ataxia - Quiver Quantitative
Solid Biosciences Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia - The Manila Times
Solid Biosciences Receives FDA Rare Pediatric Disease - GlobeNewswire
Franklin Resources Inc. Has $7.79 Million Position in Solid Biosciences Inc. $SLDB - MarketBeat
Solid Biosciences Inc (SLDB) 財務データ
収益
当期純利益
現金流量
EPS
0.80%
4.56%
大文字化:
|
ボリューム (24 時間):